BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

Reuters

08 Mar

BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

March 8 (Reuters) - Incyte Corp INCY.O:

INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS $(PN)$ AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING
INCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS
INCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCE

Source text: ID:nBw6wcHHDa

Further company coverage: INCY.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2517144198"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517144198\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517144198?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-08 22:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517144198","market":"us","top_or_hot":-1,"title":"BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints</title></head><body><p><span>March 8 (Reuters)</span><span> - </span>Incyte Corp <span>INCY.O</span>:</p><ul><li><p>INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS <a href=\"https://laohu8.com/S/PN\">$(PN)$</a> AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING</p></li><li><p>INCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS</p></li><li><p>INCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCE</p></li></ul><p>Source text: <span>ID:nBw6wcHHDa</span></p><p>Further company coverage: <span>INCY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-08 22:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<title>BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints</title><p><span>March 8 (Reuters)</span><span> - </span>Incyte Corp <span>INCY.O</span>:</p><ul><li><p>INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS <a href=\"https://laohu8.com/S/PN\">$(PN)$</a> AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING</p></li><li><p>INCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS</p></li><li><p>INCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCE</p></li></ul><p>Source text: <span>ID:nBw6wcHHDa</span></p><p>Further company coverage: <span>INCY.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250308:nTUA40P8T6:1","article_id":"2517144198","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517144198","pubTimestamp":1741442903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary EndpointsMarch 8 (Reuters) - Incyte Corp INCY.O:INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLIT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4550":"红杉资本持仓","BK4588":"碎股","BK4532":"文艺复兴科技持仓","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念"},"translate_title":"简介-Incyte Corp表示3期True-Pn1研究满足所有主要和关键次要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"BRIEF-Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary EndpointsMarch 8 (Reuters) - Incyte Corp INCY.O:INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS $(PN)$ AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETINGINCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTSINCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCESource text: ID:nBw6wcHHDaFurther company coverage: INCY.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}